Biomarker profiling of postmortem blood for diabetes mellitus and discussion of possible applications of metabolomics for forensic casework.
Biomarker
Diabetes mellitus
Liquid chromatography-mass spectrometry
Metabolomics
Phospholipids
Plasmalogen
Journal
International journal of legal medicine
ISSN: 1437-1596
Titre abrégé: Int J Legal Med
Pays: Germany
ID NLM: 9101456
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
18
08
2021
accepted:
14
12
2021
pubmed:
21
1
2022
medline:
9
6
2022
entrez:
20
1
2022
Statut:
ppublish
Résumé
Acute metabolic disorders of diabetes mellitus (DM), such as diabetic ketoacidosis, hyperosmolar hyperglycemic state, and hypoglycemia, are life-threatening and difficult to diagnose postmortem owing to lack of macroscopic and microscopic findings, especially when the medical history of the patient is not available before autopsy. Although various biochemical tests, including ketone bodies and hemoglobin A1c, have been used to diagnose diabetes in the postmortem setting, each marker has some limitations. Consequently, it would be helpful in forensic practice to find new biomarkers reflecting the decedent's history of DM irrespective of whether the DM was being treated. Metabolomics enables the non-targeting analysis of biomarkers, and metabolomics was performed on postmortem blood from decedents with and without a DM history to determine whether a marker reflecting DM could be identified. The statistical analysis, including primary component analysis, presented a potent set of metabolites that could be used for the forensic diagnosis of DM. Qualitative analysis revealed significantly lower sphingomyelin and plasmalogen lipid levels and higher lysophospholipid levels in the DM group. Meanwhile, some discrepancies in the levels of some classes of phospholipids were noted between samples from living and deceased persons. This suggests that further metabolomics using postmortem samples rather than living persons' samples is required to identify markers that can be used for forensic diagnosis.
Identifiants
pubmed: 35050412
doi: 10.1007/s00414-021-02767-w
pii: 10.1007/s00414-021-02767-w
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1075-1090Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Chen L, Magliano DJ, Zimmet PZ (2011) The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol 8(4):228–236. https://doi.org/10.1038/nrendo.2011.183
doi: 10.1038/nrendo.2011.183
pubmed: 22064493
Palmiere C (2015) Postmortem diagnosis of diabetes mellitus and its complications. Croat Med J 56(3):181–193. https://doi.org/10.3325/cmj.2015.56.181
doi: 10.3325/cmj.2015.56.181
pmcid: 4500977
pubmed: 26088843
Palmiere C, Mangin P (2012) Postmortem chemistry update part I. Int J Legal Med 126(6):187–198. https://doi.org/10.1007/s00414-011-0625-y
doi: 10.1007/s00414-011-0625-y
pubmed: 21947676
Mitchell GA, Kassovska-Bratinova S, Boukaftane Y, Robert MF, Wang SP, Ashmarina L, Lambert M, Lapierre P, Potier E (1995) Medical aspects of ketone body metabolism. Clin Invest Med 18(3):193–216
pubmed: 7554586
Winecker RE, Hammett-Stabler CA, Chapman JF, Ropero-Miller JD (2002) HbA1c as a postmortem tool to identify glycemic control. J Forensic Sci 47(6):1373–1379
doi: 10.1520/JFS15578J
pubmed: 12455667
Khuu HM, Robinson CA, Goolsby K, Hardy RW, Konrad RJ (1999) Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c. Arch Pathol Lab Med 123(9):763–767. https://doi.org/10.5858/1999-123-0763-EOAFAH
doi: 10.5858/1999-123-0763-EOAFAH
pubmed: 10458820
Lipska KJ, Warton EM, Huang ES, Moffet HH, Inzucchi SE, Krumholz HM, Karter AJ (2013) HbA1c and risk of severe hypoglycemia in type 2 diabetes. Diabetes Care 36(11):3535–3542. https://doi.org/10.2337/dc13-0610
doi: 10.2337/dc13-0610
pmcid: 3816866
pubmed: 23900589
Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, Okuno T, Hayashi N, Kawano S, Takenawa T, Azuma T, Yoshida M (2012) A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 7(7):e40459. https://doi.org/10.1371/journal.pone.0040459
doi: 10.1371/journal.pone.0040459
pmcid: 3394708
pubmed: 22792336
Thomas A, Déglon J, Lenglet S, Mach F, Mangin P, Wolfender JL, Steffens S, Staub C (2010) High-throughput phospholipidic fingerprinting by online desorption of dried spots and quadrupole-linear ion trap mass spectrometry: evaluation of atherosclerosis biomarkers in mouse plasma. Anal Chem 82(15):6687–6694. https://doi.org/10.1021/ac101421b
doi: 10.1021/ac101421b
pubmed: 20700914
Ogawa S, Hattori K, Sasayama D, Yokota Y, Matsumura R, Matsuo J, Ota M, Hori H, Teraishi T, Yoshida S, Noda T, Ohashi Y, Sato H, Higuchi T, Motohashi N, Kunugi H (2015) Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. Sci Rep 5:7796. https://doi.org/10.1038/srep07796
doi: 10.1038/srep07796
pmcid: 4295090
pubmed: 25589364
Adachi J, Matsushita S, Yoshioka N, Funae R, Fujita T, Higuchi S, Ueno Y (2004) Plasma phosphatidylcholine hydroperoxide as a new marker of oxidative stress in alcoholic patients. J Lipid Res 45(5):961–971. https://doi.org/10.1194/jlr.M400008-JLR200
doi: 10.1194/jlr.M400008-JLR200
Hammad LA, Wu G, Saleh MM, Klouckova I, Dobrolecki LE, Hickey RJ, Schnaper L, Novotny MV, Mechref Y (2009) Elevated levels of hydroxylated phosphocholine lipids in the blood serum of breast cancer patients. Rapid Commun Mass Spectrom 23(6):863–876. https://doi.org/10.1002/rcm.3947
doi: 10.1002/rcm.3947
pubmed: 19224569
Haines NR, Manoharan N, Olson JL, D’Alessandro A, Reisz JA (2018) Metabolomics analysis of human vitreous in diabetic retinopathy and rhegmatogenous retinal detachment. J Proteome Res 17(7):2421–2427. https://doi.org/10.1021/acs.jproteome.8b00169
doi: 10.1021/acs.jproteome.8b00169
pubmed: 29877085
Barnes VM, Kennedy AD, Panagakos F, Devizio W, Trivedi HM, Jönsson T, Guo L, Cervi S, Scannapieco FA (2014) Global metabolomic analysis of human saliva and plasma from healthy and diabetic subjects, with and without periodontal disease. PLoS One 18;9(8):e105181. https://doi.org/10.1371/journal.pone.0105181
doi: 10.1371/journal.pone.0105181
Abe H, Yajima D, Hoshioka Y, Nara A, Nagasawa S, Iwase H (2017) Myoglobinemia markers with potential applications in forensic sample analysis: lipid markers in myoglobinemia for postmortem blood. Int J Legal Med 131(6):1739–1746. https://doi.org/10.1007/s00414-017-1657-8
doi: 10.1007/s00414-017-1657-8
pubmed: 28812137
van Ginneken V, Verheij E, Hekman M, van der Greef J (2017) Characterization of the lipid profile post mortem for type-2 diabetes in human brain and plasma of the elderly with LCMS-techniques: a descriptive approach of diabetic encephalopathy. Integr Mol Med 4(2):1–10. https://doi.org/10.15761/IMM.1000278
doi: 10.15761/IMM.1000278
Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37(8):911–917. https://doi.org/10.1139/o59-099
doi: 10.1139/o59-099
pubmed: 13671378
Xia J, Wishart DS (2016) Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinforma 55(1):1–91. https://doi.org/10.1002/cpbi.11
doi: 10.1002/cpbi.11
Tsugawa H, Cajka T, Kind T, Ma Y, Higgins B, Ikeda K, Kanazawa M, Vandergheynst J, Fiehn O, Arita M (2015) MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nat Methods 12(6):523–526. https://doi.org/10.1038/nmeth.339310.1038/nmeth.3393
doi: 10.1038/nmeth.339310.1038/nmeth.3393
pmcid: 4449330
pubmed: 25938372
Tsugawa H, Kind T, Nakabayashi R, Yukihira D, Tanaka W, Cajka T, Saito K, Fiehn O, Arita M (2016) Hydrogen rearrangement rules: computational MS/MS fragmentation and structure elucidation using MS-FINDER software. Anal Chem 88(16):7946–7958. https://doi.org/10.1021/acs.analchem.6b00770
doi: 10.1021/acs.analchem.6b00770
pmcid: 7063832
pubmed: 27419259
Duan RD, Hertervig E, Nyberg L, Hauge T, Sternby B, Lillienau J, Farooqi A, Nilsson A (1996) Distribution of alkaline sphingomyelinase activity in human beings and animals. Tissue and species differences. Dig Dis Sci 41(9):1801–1806. https://doi.org/10.1007/BF02088748
doi: 10.1007/BF02088748
pubmed: 8794797
Stoffel W (1999) Functional analysis of acid and neutral sphingomyelinases in vitro and in vivo. Chem Phys Lipids 102(1–2):107–121. https://doi.org/10.1016/S0009-3084(99)00079-1
doi: 10.1016/S0009-3084(99)00079-1
pubmed: 11001565
Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510(7503):58–67. https://doi.org/10.1038/nature13475
doi: 10.1038/nature13475
pmcid: 4320971
pubmed: 24899305
Hailemariam TK, Huan C, Liu J, Li Z, Roman C, Kalbfeisch M, Bui HH, Peake DA, Kuo MS, Cao G, Wadgaonkar R, Jiang XC (2008) Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol 28(8):1519–1526. https://doi.org/10.1161/ATVBAHA.108.168682
doi: 10.1161/ATVBAHA.108.168682
pubmed: 18566297
Lou B, Dong J, Li Y, Ding T, Bi T, Li Y, Deng X, Ye D, Jiang XC (2014) Pharmacologic inhibition of sphingomyelin synthase (SMS) activity reduces apolipoprotein-B secretion from hepatocytes and attenuates endotoxin-mediated macrophage inflammation. PLoS ONE 9(7):e102641. https://doi.org/10.1371/journal.pone.0102641
doi: 10.1371/journal.pone.0102641
pmcid: 4102531
pubmed: 25032960
Li Z, Fan Y, Liu J, Li Y, Huan C, Bui HH, Kuo MS, Park TS, Cao G, Jiang XC (2012) Impact of sphingomyelin synthase 1 deficiency on sphingolipid metabolism and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32(7):1577–1584. https://doi.org/10.1161/ATVBAHA.112.251538
doi: 10.1161/ATVBAHA.112.251538
pmcid: 3444302
pubmed: 22580896
Ohnishi T, Hashizume C, Taniguchi M, Furumoto H, Han J, Gao R, Kinami S, Kosaka T, Okazaki T (2017) Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis-associated colon cancer. FASEB J 31(9):3816–3830. https://doi.org/10.1096/fj.201601225RR
doi: 10.1096/fj.201601225RR
pubmed: 28522594
Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, Kirwan JP (2009) Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58(2):337–343. https://doi.org/10.2337/db08-1228
doi: 10.2337/db08-1228
pmcid: 2628606
pubmed: 19008343
de Mello VD, Lankinen M, Schwab U, Kolehmainen M, Lehto S, Seppanen-Laakso T, Oresic M, Pulkkinen L, Uusitupa M, Erkkila AT (2009) Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52(12):2612–2615. https://doi.org/10.1007/s00125-009-1482-9
doi: 10.1007/s00125-009-1482-9
pubmed: 19669729
Zeghari N, Younsi M, Meyer L, Donner M, Drouin P, Ziegler O (2000) Adipocyte and erythrocyte plasma membrane phospholipid composition and hyperinsulinemia: a study in nondiabetic and diabetic obese women. Int J Obes 24(12):1600–1607. https://doi.org/10.1038/sj.ijo.0801459
doi: 10.1038/sj.ijo.0801459
Candiloros H, Zeghari N, Ziegler O, Donner M, Drouin P (1996) Hyperinsulinemia is related to erythrocyte phospholipid composition and membrane fluidity changes in obese nondiabetic women. J Clin Endocrinol Metab 81(8):2912–2918. https://doi.org/10.1210/jcem.81.8.8768851
doi: 10.1210/jcem.81.8.8768851
pubmed: 8768851
Kjellqvist S, Klose C, Surma MA, Hindy G, Mollet IG, Johansson A (2016) Identification of shared and unique serum lipid profiles in diabetes mellitus and myocardial infarction. JAHA 5(12):e004503. https://doi.org/10.1161/JAHA.116.004503
doi: 10.1161/JAHA.116.004503
pmcid: 5210412
pubmed: 27899364
Suvitaival T, Bondia-Pons I, Yetukuri L, Pöhö P, Nolan JJ, Hyötyläinen T, Kuusisto J, Orešič M (2018) Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men. Metabolism 78:1–12. https://doi.org/10.1016/j.metabol.2017.08.014
doi: 10.1016/j.metabol.2017.08.014
pubmed: 28941595
Morand OH, Zoeller RA, Raetz CR (1988) Disappearance of plasmalogens from membranes of animal cells subjected to photosensitized oxidation. J Biol Chem 263(23):11597–11606
doi: 10.1016/S0021-9258(18)38001-3
pubmed: 3403548
Khaselev N, Murphy RC (1999) Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic Biol Med 26(3–4):275–284. https://doi.org/10.1016/S0891-5849(98)00211-1
doi: 10.1016/S0891-5849(98)00211-1
pubmed: 9895217
Maeba R, Sawada Y, Shimasaki H, Takahashi I, Ueta N (2002) Ethanolamine plasmalogens protect cholesterol-rich liposomal membranes from oxidation caused by free radicals. Chem Phys Lipids 120(1–2):145–151. https://doi.org/10.1016/S0009-3084(02)00101-9
doi: 10.1016/S0009-3084(02)00101-9
pubmed: 12426083
Skaff O, Pattison DI, Davies MJ (2008) The vinyl ether linkages of plasmalogens are favored targets for myeloperoxidase-derived oxidants: a kinetic study. Biochemistry 47(31):8237–8245. https://doi.org/10.1021/bi800786q
doi: 10.1021/bi800786q
pubmed: 18605737
Broniec A, Klosinski R, Pawlak A, Wrona-Krol M, Thompson D, Sarna T (2011) Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model systems. Free Radic Biol Med 50(7):892–898. https://doi.org/10.1016/j.freeradbiomed.2011.01.002
doi: 10.1016/j.freeradbiomed.2011.01.002
pmcid: 3073128
pubmed: 21236336
Tangvarasittichai S (2015) Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes 6(3):456–480. https://doi.org/10.4239/wjd.v6.i3.456
doi: 10.4239/wjd.v6.i3.456
pmcid: 4398902
pubmed: 25897356
Fuchs B (2014) Mass spectrometry and inflammation—MS methods to study oxidation and enzyme-induced changes of phospholipids. Anal Bioanal Chem 406(5):1291–1306. https://doi.org/10.1007/s00216-013-7534-5
doi: 10.1007/s00216-013-7534-5
pubmed: 24363111
Fang L, Harkewicz R, Hartvigsen K, Wiesner P, Choi SH, Almazan F, Pattison J, Deer E, Sayaphupha T, Dennis EA, Witztum JL, Tsimikas S, Miller YI (2010) Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation. J Biol Chem 285(42):32343–32351. https://doi.org/10.1074/jbc.M110.137257
doi: 10.1074/jbc.M110.137257
pmcid: 2952235
pubmed: 20710028
Ha CY, Kim JY, Paik JK, Kim OY, Paik YH, Lee EJ, Lee JH (2012) The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf) 76(5):674–682. https://doi.org/10.1111/j.1365-2265.2011.04244.x
doi: 10.1111/j.1365-2265.2011.04244.x
Wang C, Kong H, Guan Y, Yang J, Gu J, Yang S, Xu G (2005) Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 77(13):4108–4116. https://doi.org/10.1021/ac0481001
doi: 10.1021/ac0481001
pubmed: 15987116